Treatment of Pelvic Endometriosis with Gestrinone ‐Report on 9 Cases ‐

T Tamaya, Teruhiko Tama‐a, Tamaya T, Jiro Fujimoto, J Fujimoto, Fujimoto J, Okada H, H Okada, Hiroji Okada
Asia-Oceania journal of obstetrics and gynaecology · 1985 · vol. 11(3) , pp. 403–409 · doi:10.1111/j.1447-0756.1985.tb00762.x · PMID:3853455 · W1965835127
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-26 ⓘ

Nine endometriosis patients treated with gestrinone showed reduced objective findings and amenorrhea, with side effects including acne, discharge, hoarseness, and elevated transaminases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Abstract Nine patients with pelvic endometriosis were treated with gestrinone in a dose of 2.5 mg twice weekl‐ for 6 to 7 months. All patients became anovulator‐ with sporadic episodes of painless uterine bleeding lasting various periods of time, until the‐ became amenorrheic. Considerable lessening of the objective findings such as nodular lesions in the posterior cul‐de‐sac, adnexal mass, uterine mobilit‐ and pelvic tenderness were found. Major side effects recorded were acne in 2 patients, transient increased discharge in 3 patients, and hoarseness in 1 patient. Abnormal increase of serum transaminases was observed in 3 patients, who did not discontinue tne therap‐. Follow‐up of 8 patients until 12 weeks after discontinuation of therap‐ showed that ovulation, determined b‐ basal bod‐ temperature, returned within 7 to 50 (22.8 + 4.9[SE]) da‐s and that objective findings were not remarkabl‐ changed, but subjective findings such as pelvic pain in menses reappeared in 5 of 8 patients.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gestrinone Norpregnatrienes Pelvic Neoplasms Adult Endometriosis Female Gestrinone Gestrinone Humans Norpregnatrienes Pelvic Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (1)

Source provenance

europepmc
last seen: 2026-08-07T06:07:27.085738+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:45.632124+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK